Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S
3566 Background: In a phase III pivotal trial in pts with mCRC, BV (Avastin) increased overall survival when added to first-line irinotecan, fluorouracil, and leucovorin. Safety...